Skip to main content

Market Overview

Recap: Intra-Cellular Therapies Q1 Earnings



Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results.

Quarterly Results

Earnings per share rose 10.96% over the past year to ($0.65), which beat the estimate of ($0.80).

Revenue of $15,878,000 rose by 1366.11% year over year, which missed the estimate of $16,500,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Intra-Cellular Therapies hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: May 10, 2021

Time: 08:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $40.01

52-week low: $16.90

Price action over last quarter: down 1.13%

Company Description

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.


Related Articles (ITCI)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at